The BRAVE trial is testing whether weight loss surgery prevents heart attacks and strokes better than medical treatment in people with obesity and existing heart disease. According to Gram Research analysis, this randomized controlled trial has enrolled 200 high-risk participants so far across 17 centers in four countries. The study found that 82% of participants have high blood pressure, 48% have irregular heartbeat, and 44% have coronary artery disease. Final results comparing surgery outcomes to medical treatment aren’t available yet, but this is the first large-scale trial to properly test whether surgery actually prevents heart events.
Researchers are running a major study called BRAVE to find out whether weight loss surgery can prevent heart attacks and strokes in people with obesity who already have heart problems. According to Gram Research analysis, this is the first large-scale test comparing weight loss surgery directly to medical weight management in high-risk patients. The study includes 200 people so far from hospitals in Canada, Brazil, Italy, and Spain. Participants either get weight loss surgery or receive intensive medical treatment including diet changes, behavior coaching, and medications. The researchers will track whether surgery reduces serious heart events better than medical treatment alone.
Key Statistics
A 2026 randomized controlled trial called BRAVE enrolled 200 participants with obesity and existing heart disease from 17 medical centers across Canada, Brazil, Italy, and Spain to test whether weight loss surgery prevents heart attacks better than medical treatment.
In the BRAVE trial’s vanguard phase, 82% of the 200 enrolled participants had high blood pressure, 48% had atrial fibrillation (irregular heartbeat), and 44% had coronary artery disease, representing a high-risk population.
The BRAVE trial screened 2,514 individuals and successfully randomized 200 into the study as of October 2025, demonstrating feasible recruitment after addressing initial enrollment barriers through enhanced patient education.
Among BRAVE trial participants, the average age was 59.8 years with a mean BMI of 44.0 kg/m², and 39% had heart failure, making this the first large randomized trial to evaluate weight loss surgery’s impact on cardiovascular events in high-risk patients.
The Quick Take
- What they studied: Whether weight loss surgery prevents heart attacks, strokes, and other serious heart problems better than medical weight management in people with obesity and existing heart disease.
- Who participated: 200 people (so far) with an average age of 60, mostly overweight or obese, with many having high blood pressure, diabetes, or previous heart problems. About 37% were women.
- Key finding: This is a vanguard phase (early testing stage) of a larger study. Researchers have successfully enrolled 200 participants and identified ways to improve recruitment. The study is still ongoing and hasn’t yet compared surgery outcomes to medical treatment.
- What it means for you: If you have obesity and heart disease, this research may eventually help doctors decide whether weight loss surgery is a better option than medication and lifestyle changes. Results won’t be available for several more years.
The Research Details
BRAVE is a randomized controlled trial, which is the gold standard for medical research. Researchers randomly assigned 200 people into two groups: one group receives weight loss surgery (either sleeve gastrectomy, gastric bypass, or duodenal switch), while the other group receives intensive medical treatment including dietary changes, behavioral coaching, and weight loss medications.
The study is “open-label,” meaning both patients and doctors know who gets surgery versus medical treatment. However, the researchers use “blinded endpoint adjudication,” which means the doctors who evaluate whether serious health events occurred don’t know which treatment group each patient received. This prevents bias in determining outcomes.
The study involves 17 medical centers across Canada, Brazil, Italy, and Spain. Participants must have obesity (BMI of 35 or higher, or 30+ with diabetes or age over 55) and existing heart disease such as previous heart attacks, heart failure, irregular heartbeat, or stroke.
Previous studies have only observed that people who get weight loss surgery seem to have fewer heart attacks and strokes. However, observation studies can’t prove surgery causes the improvement—it could be that healthier people choose surgery. A randomized controlled trial randomly assigns people to treatment, which proves whether surgery actually prevents heart problems. This is the first large trial to test this question properly.
This is a high-quality study design published in a respected medical journal. The vanguard phase (early stage with 200 people) successfully demonstrated that recruitment is feasible and identified problems that were then fixed. The study includes multiple centers across different countries, making results more generalizable. The blinded endpoint evaluation reduces bias. However, this is only the vanguard phase—the full study will include more participants and take several more years to complete.
What the Results Show
As of October 2025, researchers screened 2,514 people and successfully randomized 200 into the study. This shows that recruitment is working, though slower than initially hoped. The 200 randomized participants have an average age of 59.8 years, with 37% women. They have significant health problems: 82% have high blood pressure, 45% have diabetes, 44% have coronary artery disease, 39% have heart failure, and 48% have atrial fibrillation (irregular heartbeat).
The researchers identified specific barriers to recruitment and successfully addressed them through better patient education and engagement strategies. These improvements will help the full study enroll participants more efficiently.
The study is tracking a composite primary outcome—meaning researchers will count any occurrence of death from any cause, heart attack, stroke, heart failure events, need for coronary procedures, hospitalization for irregular heartbeat, or kidney problems. This comprehensive approach captures the full impact of weight loss surgery on heart health.
The study is still in its vanguard phase, so detailed outcome comparisons between surgery and medical treatment groups are not yet available. Secondary analyses will eventually examine how different types of weight loss surgery compare to each other, how quickly benefits appear, and whether certain patient groups benefit more than others.
Previous observational studies suggested weight loss surgery reduces death and heart problems in people with obesity. However, these studies couldn’t prove surgery caused the improvement because they only watched what happened—they didn’t randomly assign people to treatment. BRAVE is the first large randomized trial to test whether surgery actually prevents heart events better than intensive medical management. This addresses a major gap in medical evidence.
This is only the vanguard phase with 200 participants, so final results comparing surgery to medical treatment aren’t available yet. The study is open-label, meaning patients and doctors know who gets surgery, which could influence behavior. The study focuses on high-risk patients with existing heart disease, so results may not apply to people with obesity but no heart problems. Results won’t be available for several more years.
The Bottom Line
This study is still ongoing and hasn’t yet provided evidence about whether weight loss surgery prevents heart attacks better than medical treatment. If you have obesity and heart disease, discuss all treatment options—including weight loss surgery and medical management—with your cardiologist. Don’t make decisions based on this vanguard phase alone; wait for final results or consult your doctor about current evidence.
This research is most relevant to people with obesity who have experienced heart attacks, strokes, heart failure, or irregular heartbeat. It’s also important for cardiologists and weight loss surgeons deciding how to treat high-risk patients. People with obesity but no heart disease should wait for additional research before assuming surgery is necessary.
The full BRAVE study will take several more years to complete. Researchers need to enroll more participants, follow them over time, and track whether serious heart events occur. Preliminary results may appear in 2-3 years, with complete results likely 4-5 years away.
Frequently Asked Questions
Does weight loss surgery prevent heart attacks?
The BRAVE trial is testing this question now. Previous observational studies suggest surgery may help, but this is the first large randomized trial to prove whether it actually prevents heart attacks. Results won’t be available for several more years.
Who should consider weight loss surgery if they have heart disease?
The BRAVE trial focuses on people with obesity (BMI 35+) who have had heart attacks, strokes, heart failure, or irregular heartbeat. Discuss with your cardiologist whether surgery is appropriate for your specific situation.
What types of weight loss surgery does the BRAVE study use?
The BRAVE trial uses three types: sleeve gastrectomy (removing part of the stomach), Roux-en-Y gastric bypass (rerouting the small intestine), and duodenal switch (combining both approaches). Your surgeon determines which is best for you.
When will the BRAVE trial results be available?
This vanguard phase with 200 participants is still ongoing. The full study will take several more years to complete. Preliminary findings may appear in 2-3 years, with complete results expected 4-5 years away.
How does weight loss surgery compare to diet and medication for heart health?
The BRAVE trial is directly comparing these approaches. Currently, we don’t have definitive evidence from randomized trials. The study will show whether surgery provides additional heart protection beyond what diet, behavior changes, and medications can achieve.
Want to Apply This Research?
- If enrolled in a weight loss program, track weekly weight, blood pressure readings, and medication changes. Record any chest pain, shortness of breath, or irregular heartbeat episodes immediately.
- Users considering weight loss options should log daily food intake, exercise minutes, and mood to establish baseline habits before any intervention. This creates a comparison point for measuring progress.
- Establish a monthly check-in routine to review weight trends, cardiovascular symptoms, and medication adherence. Set alerts for annual heart health screenings and doctor appointments.
This article describes a clinical trial in progress and should not be interpreted as medical advice. Weight loss surgery carries risks and benefits that vary by individual. If you have obesity and heart disease, consult with your cardiologist and a bariatric surgeon to discuss whether surgery is appropriate for your situation. Do not make treatment decisions based on this research summary alone. Always follow your doctor’s recommendations and seek immediate medical attention for chest pain, shortness of breath, or other cardiac symptoms.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.